FDA approves Sorrento’s non-opioid pain patch for post-herpetic neuralgia

This article was originally published here

Sorrento Therapeutics’ subsidiary Scilex Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for non-opioid ZTlido (lidocaine topical system) 1.8% to relieve pain associated with post-herpetic neuralgia (PHN) or post-shingles pain.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply